Peran Steroid pada Pneumocystis Pneumonia Ditinjau Berdasarkan Imunopatogenesis
[Immunopathogenesis of Steroid in Pneumocystis Pneumonia]
Pneumocystis Pneumonia (PCP) is a potentially life-threatening infection that can occur in individuals who are immunocompromised. In PCP steroid use is still recommended especially in patients with moderate and severe severity. Corticosteroids are given along with anti-pneumocystis therapy and are known to reduce the incidence of mortality and respiratory failure associated with PCP. Innate immunity and adaptive immunity are symbiotic relationships to provide optimal defense for the lungs and other organs and tissues from infection PCP. The corticosteroid mechanism in PCP is based on an anti-inflammatory mechanism especially its role in inhibiting neutrophils. Many clinicians believe the administration of anti-pneumocystis causes the acceleration of inflammation. Because the inflammatory process increases when anti-pneumocystis therapy is started, corticosteroid therapy is useful before inflammation occurs which causes extensive damage to the lungs.
Omny A, Bagus SI. Aspek Pulmonologis Infeksi Oportunistik pada Infeksi HIV/AIDS. J Penyakit Dalam Indones. 2017;134(4):635–46.
Taylor John Eddens. Host-Pathogen Interactions in Pneumocystis Infection. University of Pittsburgh; 2016.
Alferd F, J E, J F, M G, Robert SM, I PA. Fishman’s Pulmonary Diseases and Disorders. fourth edi. P FA, editor. Vol. 39, Animal Genetics. New York: Mc Graw Hill Medical; 2008. 561-563.
Baxter R, Hastings N, Law A, Glass EJ. Principles of Pulmonary Medicine. 5th ed. Steven E. Weinberger, MD F, Barbara A. Cockrill M, Jess Mandel, MD F, editors. Vol. 39, Animal Genetics. Philadelphia: Saunders, Elesevier; 2008. 561-563.
Becker DE. Basic and Clinical Pharmacology of Glucocorticosteroids. Am Dent Soc Anesthesiol. 2013;3006(13):25–32.
Sethi GR, Singhal KK. Pulmonary Diseases and Corticosteroids. Indian J Pediatr. 2008;75:1045–54.
Gigliotti F, Wright TW. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med. 2005;7(26):1–16.
Frunza-Stefan S, Acharya G, Kazlouskaya V, Vukasinov P, Chiou Y, Thet Z. Immune reconstitution inflammatory syndrome associated with secondary syphilis. Int J STD AIDS. 2017;28(3):302–5.
Thomas CF, Limper AH. Pneumocystis Pneumonia. N Engl J Med. 2004;2487–98.
Hutagalung SV. Pneumocystis carinii Pneumonia Suatu Infeksi Oportunistik. USU Repository. Universitas Sumatera Utara; 2008.
Centers for Disease Control and Prevention. Pneumocystis [Internet]. 2019. p. 2–4. Available from: https://www.cdc.gov/dpdx/pneumocystis/index.html
V. Courtney Broaddus. Murray and Nadel’s Textbook of Respiratory Medicine [Internet]. sixth. V. Courtney Broaddus, editor. Philadelphia: Elsevier Inc; 2016. i-ii. Available from: http://linkinghub.elsevier.com/retrieve/pii/B9781455733835001305
Kelly MN. Current Understanding of Pneumocystis Immunology. Futur Microbiol. 2013;5(1):43–65.
Prévost MC, Escamilla R, Aliouat EM, Ceré N, Coudert P, Dei-Cas E. XV. Pneumocystosis pathophysiology. FEMS Immunol Med Microbiol. 1998;22(1–2):123–8.
Yudhawati R, Prasetiyo YD. Imunopatogenesis Penyakit Paru Obstruktif Kronik. Jurnal Respirasi. 2018;4(1):19-25.
Allister FM, Steele C, Zheng M, Shellito JE, Marrero L, Kolls JK, et al. T Cytotoxic-1 CD8 + T Cells Are Effector Cells against Pneumocystis in Mice. J Immunol [Internet]. 2019; Available from: http://www.jimmunol.org/content/172/2/1132.full#ref-list-1
Kolls JK, Habetz S, Shean MK, Vazquez C, Brown JA, Lei D, et al. IFN- γ and CD8 + T Cells Restore Host Defenses Against Pneumocystis carinii in Mice Depleted of CD4 + T Cells. N Engl J Med [Internet]. 2019;4–9. Available from: www.jimmunol.org/content/162/5/2890.full#ref-list-1
Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection. Semin Immunopathol. 2014;
Su, M.D TH, Martin II, M.D WJ. Pathogenesis and Host Response in Pneumocystis carinii Pneumonia. Annu Rev Med [Internet]. 1994;45(1):261–72. Available from: http://www.annualreviews.org/doi/10.1146/annurev.med.45.1.261
Gigliotti F, Wright TW. Pneumocystis : Where Does It Live ? PLoS Pathog. 2012;8(11):8–11.
Abduljabbar H. Steroid – Basic Science [Internet]. Rijeka: InTech; 2011. 3-35 p. Available from: www.intechopen.com
Sulistia GG. Farmakologi dan Terapi. 5th ed. Jakarta: Departemen Farmakologi dan Terapi Fakultas Kedokteran UI; 2008.
Gupta P, Bhatia V. Corticosteroid Physiology and Principles of Therapy. Indian J Pediatr. 2008;75:1039–44.
Bozzette SA. The Use of Corticosteroids in Pneumocystis carinii Pneumonia. J Infect Dis. 1990;162:1365–9.
Coutinho AE, Chapman KE. Molecular and Cellular Endocrinology The anti-inflammatory and immunosuppressive effects of glucocorticoids , recent developments and mechanistic insights. Mol Cell Endocrinol [Internet]. 2011;335(1):2–13. Available from: http://dx.doi.org/10.1016/j.mce.2010.04.005
Pneumonia TNI of H-U of CEP for C as AT for P. Consensus Statement on the use of Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia in the Acquired Immunideficiency Syndrome. N Engl J Med [Internet]. 1990;323:1500. Available from: NEJM.org
Butler T. Review Article The Jarisch – Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections : A Review of Recent Cases and Our Understanding of Pathogenesis. 2017;96(1):46–52.
Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA, et al. Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest [Internet]. 2018; Available from: https://doi.org/10.1016/j.chest.2018.04.026
Ewald H, Raatz H, Boscacci R, Furrer H, Hc B, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection ( Review ). Cochrane Collab. 2015;(4).
Briel M, Bucher H, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection ( Review ). 2009;(3).
Wang LI, Liang HAO, Ye LI, Jiang J, Liang B, Huang J. Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV : A meta ‑ analysis. Exp Ther Med. 2016;(March 2014):683–7.
Moon SM, Kim T, Sung H, Kim M, Kim S, Choi S, et al. Outcomes of Moderate-to-Severe Pneumocystis Pneumonia Treated with Adjunctive Steroid in Non-HIV-Infected Patients. Antimocrobial Agents Chemother [Internet]. 2011;55(10):4613–8. Available from: https://aac.asm.org/
Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect [Internet]. 2014;44(5):185–98. Available from: http://dx.doi.org/10.1016/j.medmal.2014.01.007
Copyright (c) 2020 Resti Yudhawati, Whendy Wijaksono
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.